Salix Pharmaceuticals Ltd. Sets New 1-Year High at $92.31 (SLXP)
Shares of Salix Pharmaceuticals (NASDAQ:SLXP) hit a new 52-week high during mid-day trading on Friday, StockRatingsNetwork.com reports. The stock traded as high as $92.31 and last traded at $91.24, with a volume of 707,889 shares trading hands. The stock had previously closed at $89.09.
A number of research firms have recently commented on SLXP. Analysts at Stifel Nicolaus upgraded shares of Salix Pharmaceuticals from a “hold” rating to a “buy” rating in a research note to investors on Tuesday, December 17th. They now have a $108.00 price target on the stock. Separately, analysts at Janney Montgomery Scott reiterated a “buy” rating on shares of Salix Pharmaceuticals in a research note to investors on Tuesday, November 19th. They now have a $95.00 price target on the stock. Finally, analysts at Susquehanna raised their price target on shares of Salix Pharmaceuticals from $75.00 to $81.00 in a research note to investors on Monday, November 11th. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $80.80.
Salix Pharmaceuticals (NASDAQ:SLXP) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.89 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.86 by $0.03. The company had revenue of $238.20 million for the quarter, compared to the consensus estimate of $239.70 million. During the same quarter last year, the company posted $0.95 earnings per share. Salix Pharmaceuticals’s revenue was up 28.7% compared to the same quarter last year.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.